Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical Orthopaedics and Related Research|June 6, 2007
Clinical experience with daptomycin treatment of foot or ankle osteomyelitis: a preliminary studyPaul D Holtom, Charalampos G Zalavras, Kenneth C Lamp, et al.
Diagnostic Microbiology and Infectious Disease|July 11, 2002
Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000Roger L White, Kevin A Enzweiler, Lawrence V Friedrich, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2016
Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection ModelBrian D VanScoy, Michael Trang, Jennifer McCauley, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase InhibitorPaul G Ambrose, Brian D VanScoy, Michael Trang, et al.
Antimicrobial Agents and Chemotherapy|July 30, 2014
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection modelBrian D VanScoy, Rodrigo E Mendes, Mariana Castanheira, et al.
International Journal of Antimicrobial Agents|December 10, 2016
In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection modelRachel L Soon, Justin R Lenhard, Zackery P Bulman, et al.
Antimicrobial Agents and Chemotherapy|January 6, 2016
Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor CombinationsRachel L Soon, Justin R Lenhard, Zackery P Bulman, et al.
Pharmacotherapy|May 14, 2003
Assessment of differences in antimicrobial effect determined with two in vitro pharmacodynamic models: impact of surface area to volume ratioRoger L White, Charles R Bonapace, Lawrence V Friedrich, et al.
Antimicrobial Agents and Chemotherapy|June 19, 2013
Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection modelBrian Vanscoy, Rodrigo E Mendes, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2013
Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with CeftolozaneBrian Vanscoy, Rodrigo E Mendes, Jennifer McCauley, et al.
Pageof 3